The regulatory green light follows successful Phase 3 trial results, confirming the efficacy of capivasertib—the active component in Truqap—for patients who have not yet developed resistance to standard hormone-blocking treatments. Alongside the drug approval, the FDA sanctioned a companion diagnostic test designed to identify PTEN deficiencies within prostate adenocarcinoma tumors. By pinpointing these specific genetic markers, clinicians can now offer a more tailored approach to patients previously categorized under broader diagnostic labels. AstraZeneca is currently pursuing similar regulatory clearance for this treatment regimen within the European Union, aiming to expand access to this targeted therapy beyond the U.S. market.